BMO Capital Reiterates Market Perform Rating on Merus N.V. (MRUS), offers bullish comments

BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $97.00 price target on Merus N.V. (NASDAQ: MRUS).

The analyst commented: "Today's presentation solidifies petosemtamab as an encouraging potential option in the 1L and 2L setting for patients with mCRC. • Updated data shared demonstrates a compelling early efficacy profile where petosemtamab reached ORRs (including confirmed and unconfirmed responses in 1L and 2L) of 80%, 62%, and 10% in 1L, 2L, and 3L mCRC (July 29 cut-off), respectively, though small ns and unconfirmed responses make interpretation a little less clean. • All in, we arebullish on the closing of the Genmab-Merus deal with today's update not enough to meaningfully change deal negotiations."

For an analyst ratings summary and ratings history on Merus N.V. click here. For more ratings news on Merus N.V. click here.

Shares of Merus N.V. closed at $95.06 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy